A Study of Brenipatide in Adult Participants With Schizophrenia
Phase 2
18–55
31 sites in AR, CA, CT +12
About this study
This Phase 2 study is focused on people with schizophrenia. The primary outcome being measured is Percent Change from Baseline in Body Weight in Participants with a Baseline Body Mass Index ≥25.0 Kilograms per Meter Squared (kg/m²).
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Percent Change from Baseline in Body Weight in Participants with a Baseline Body Mass Index ≥25.0 Kilograms per Meter Squared (kg/m²)
Secondary: Change from Baseline in Clinical Global Impression - Severity - Schizophrenia (CGI-S-SCH), Change from Baseline in Patient Global Impression - Severity, Change from Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score, Change from Baseline on Neurocognitive Battery Composite Test Score at Week 36, Change from Baseline on the Schizophrenia Cognition Rating Scale (SCoRS) Total Score, Change from Baseline on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) Total Completion Time, Percentage of Participants with Body Mass Index ≥25 kg/m2 (BMI) Who Achieve Body Weight Reduction of ≥5%, Pharmacokinetic (PK): Average Steady State Plasma Concentration (Cavg) of Brenipatide
Psychiatry / Mental Health